{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:45:45Z","timestamp":1789055145834,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ncl.2025.12.003","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:44:51Z","timestamp":1770381891000},"page":"149-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Updates on the Acute and Maintenance Management of Optic Neuritis Including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody Disease"],"prefix":"10.1016","volume":"44","author":[{"given":"Abdul Rahman","family":"Alchaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ncl.2025.12.003_bib1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1474-4422(16)30237-X","article-title":"Diagnosis and clinical features of common optic neuropathies","volume":"15","author":"Biousse","year":"2016","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2025.12.003_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ncl.2025.12.003_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.003_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody\u2013associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2025.12.003_bib5","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"issue":"Pt 1","key":"10.1016\/j.ncl.2025.12.003_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/brain\/awu335","article-title":"Vision and vision-related outcome measures in multiple sclerosis","volume":"138","author":"Balcer","year":"2015","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.ncl.2025.12.003_bib7","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.003_bib8","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1038\/s41598-024-57199-4","article-title":"Clinical and paraclinical characteristics of optic neuritis in the context of the McDonald criteria 2017","volume":"14","author":"Jendretzky","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ncl.2025.12.003_bib9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/jon.13137","article-title":"MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease","volume":"33","author":"Carnero Contentti","year":"2023","journal-title":"J Neuroimaging"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.003_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1474-4422(22)00187-9","article-title":"Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment","volume":"22","author":"Bennett","year":"2023","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.003_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol"},{"key":"10.1016\/j.ncl.2025.12.003_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jns.2016.06.036","article-title":"Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"367","author":"Masuda","year":"2016","journal-title":"J Neurol Sci"},{"issue":"10","key":"10.1016\/j.ncl.2025.12.003_bib13","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2024.2811","article-title":"Time to treat first acute attack of myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"81","author":"Kwon","year":"2024","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.003_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/ijms22010100","article-title":"Myelin oligodendrocyte glycoprotein antibody\u2013associated disease: current insights into the disease pathophysiology, diagnosis, and management","volume":"22","author":"Ambrosius","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.003_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of MOG-IgG optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2025.12.003_bib86","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/WNO.0000000000002116","article-title":"Ocular manifestations of multiple sclerosis: a population-based study","volume":"44","author":"Kraker","year":"2024","journal-title":"J Neuro Ophthalmol"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.003_bib87","first-page":"151","article-title":"Optic neuritis, the most common initial presenting manifestation of multiple sclerosis in northern Iran","volume":"6","author":"Hojjati","year":"2015","journal-title":"Caspian J Intern Med"},{"issue":"9","key":"10.1016\/j.ncl.2025.12.003_bib88","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2025.12.003_bib89","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses, and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.ncl.2025.12.003_bib16","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMcp053247","article-title":"Optic neuritis","volume":"354","author":"Balcer","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.003_bib17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2025.12.003_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1468-1331.2008.02146.x","article-title":"Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis","volume":"15","author":"Perumal","year":"2008","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2025.12.003_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288366","article-title":"Effectiveness of oral prednisone tapering following intravenous methylprednisolone for acute optic neuritis in multiple sclerosis","volume":"18","author":"Wilf-Yarkoni","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.003_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2025.12.003_bib21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.003_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/ICU.0000000000001007","article-title":"Evidence-based management of optic neuritis","volume":"35","author":"Bergeron","year":"2024","journal-title":"Curr Opin Ophthalmol"},{"issue":"11","key":"10.1016\/j.ncl.2025.12.003_bib23","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1468-1331.2008.02258.x","article-title":"Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin","volume":"15","author":"Tselis","year":"2008","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2025.12.003_bib24","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1007\/s00415-020-10257-z","article-title":"Therapeutic plasma exchange vs conventional treatment with intravenous high-dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis","volume":"268","author":"Siritho","year":"2021","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.003_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.003_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jnnp-2022-330360","article-title":"Time to steroids impacts visual outcome of optic neuritis in MOGAD","volume":"94","author":"Rode","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2025.12.003_bib27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(20)30432-4","article-title":"Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care","volume":"20","author":"Fadda","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2025.12.003_bib28","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1007\/s00415-023-11920-x","article-title":"An update on optic neuritis","volume":"270","author":"Kraker","year":"2023","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.003_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0002-9394(01)01209-0","article-title":"Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis","volume":"132","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.003_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","article-title":"REFLEX trial: subcutaneous interferon beta-1a after a first clinical demyelinating event","volume":"11","author":"Comi","year":"2012","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2025.12.003_bib31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2025.12.003_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1474-4422(25)00275-3","article-title":"The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis","volume":"24","author":"Saidha","year":"2025","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2025.12.003_bib33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult MOGAD","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.003_bib34","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209624","article-title":"Early maintenance treatment after a first event of MOGAD in adults (MOGADOR2)","volume":"103","author":"Deschamps","year":"2024","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.003_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2025.12.003_bib36","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective therapy for RRMS","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2025.12.003_bib37","first-page":"2139","article-title":"Time matters in multiple sclerosis","volume":"145","author":"Brown","year":"2022","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.ncl.2025.12.003_bib38","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.ncl.2025.12.003_bib39","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"Interferon beta-1b in multiple sclerosis: final outcome of the RCT","volume":"45","year":"1995","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ncl.2025.12.003_bib40","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer-1 in relapsing-remitting MS: RCT","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2025.12.003_bib41","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for RRMS","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ncl.2025.12.003_bib42","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1212\/WNL.0000000000001462","article-title":"Long-term effects of fingolimod in multiple sclerosis: FREEDOMS extension","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.003_bib43","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab vs teriflunomide in relapsing MS (ASCLEPIOS I\/II)","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ncl.2025.12.003_bib44","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab vs teriflunomide in relapsing MS","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.003_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ncl.2025.12.003_bib46","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"AFFIRM investigators. Natalizumab for relapsing MS","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ncl.2025.12.003_bib47","first-page":"990","article-title":"Alemtuzumab CARE-MS II: six-year follow-up","volume":"16","author":"Coles","year":"2017","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.003_bib48","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/13524585241231665","article-title":"Autologous HSCT for multiple sclerosis: long-term follow-up from Norway","volume":"30","author":"Kvistad","year":"2024","journal-title":"Mult Scler"},{"issue":"19","key":"10.1016\/j.ncl.2025.12.003_bib49","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in non-relapsing SPMS","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ncl.2025.12.003_bib50","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1474-4422(25)00174-7","article-title":"Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study","volume":"24","author":"Bar-Or","year":"2025","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2025.12.003_bib52","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/brain\/awae409","article-title":"De-escalating and discontinuing DMTs in MS","volume":"148","author":"Androdias","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2025.12.003_bib53","article-title":"Effects of early intervention in AQP4+ NMOSD","volume":"15","author":"Xue","year":"2024","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ncl.2025.12.003_bib54","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1111\/ene.15425","article-title":"Optimal treatment duration and risk of discontinuation in NMOSD","volume":"29","author":"Li","year":"2022","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.003_bib55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00415-025-13125-w","article-title":"Relapse risk after rituximab discontinuation in NMOSD: multicenter cohort","volume":"272","author":"Hu","year":"2025","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2025.12.003_bib56","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in AQP4+ NMOSD (PREVENT)","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.003_bib57","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of eculizumab in AQP4-IgG+ NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.003_bib58","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in AQP4+ NMOSD (CHAMPION-NMOSD)","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2025.12.003_bib59","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00415-025-13279-7","article-title":"Immunotherapies in neuromyelitis optica: bayesian network meta-analysis","volume":"272","author":"John","year":"2025","journal-title":"J Neurol"},{"issue":"10206","key":"10.1016\/j.ncl.2025.12.003_bib60","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for NMOSD (N-MOmentum): phase 2\/3 RCT","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.003_bib61","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","article-title":"Inebilizumab: end-of-study results from N-MOmentum OLE","volume":"23","author":"Cree","year":"2024","journal-title":"Lancet Neurol"},{"issue":"22","key":"10.1016\/j.ncl.2025.12.003_bib62","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in NMOSD","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ncl.2025.12.003_bib63","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Rituximab in NMOSD: systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.003_bib64","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"RIN-1: randomized, double-blind, placebo-controlled rituximab trial in NMOSD","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2025.12.003_bib65","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1177\/1352458518776584","article-title":"Treating NMOSD with azathioprine: 20-year practice","volume":"25","author":"Bichuetti","year":"2019","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.ncl.2025.12.003_bib66","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/ene.15355","article-title":"Azathioprine, mycophenolate, and reduced-dose rituximab in NMOSD: efficacy and safety","volume":"29","author":"Huang","year":"2022","journal-title":"Eur J Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2025.12.003_bib67","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in NMOSD (AQP4-IgG, MOG-IgG, seronegative)","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.ncl.2025.12.003_bib68","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta in NMOSD: increased relapses and AQP4 titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2025.12.003_bib69","series-title":"27th ECTRIMS Congress","article-title":"Severe exacerbations of NMOSD during natalizumab therapy","author":"Kleiter","year":"2011"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.003_bib70","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ana.26731","article-title":"Early relapses and long-term relapsing risk in MOGAD","volume":"94","author":"Chen","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2025.12.003_bib71","article-title":"MOGAD: clinical\/mri features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2025.12.003_bib72","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOGAD: international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.ncl.2025.12.003_bib73","article-title":"Rituximab for relapse prevention in MOGAD: systematic review and meta-analysis","volume":"364","author":"Nepal","year":"2022","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.ncl.2025.12.003_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104571","article-title":"Effectiveness of relapse prevention therapy for MOGAD: meta-analysis","volume":"72","author":"Chang","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.003_bib75","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200150","article-title":"Dramatic response to anti\u2013IL-6 receptor therapy in pediatric life-threatening MOGAD","volume":"10","author":"McLendon","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.003_bib76","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archopht.1993.01090060061023","article-title":"Optic neuritis treatment trial. One-year follow-up results","volume":"111","author":"Beck","year":"1993","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.ncl.2025.12.003_bib77","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/jnnp-2023-333133","article-title":"Prognostic factors of first-onset optic neuritis by criteria and antibody status: multicentre analysis of 427 eyes","volume":"95","author":"Min","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.003_bib78","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in MS","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet Neurol"},{"issue":"22","key":"10.1016\/j.ncl.2025.12.003_bib79","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1212\/WNL.0000000000004681","article-title":"High risk of postpartum relapses in NMOSD","volume":"89","author":"Klawiter","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2025.12.003_bib80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejogrb.2021.02.027","article-title":"Therapeutic plasma exchange in pregnancy: literature review","volume":"260","author":"Wind","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"9","key":"10.1016\/j.ncl.2025.12.003_bib81","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/jnnp-2022-330533","article-title":"Postpartum relapse risk in multiple sclerosis: systematic review and meta-analysis","volume":"94","author":"Schubert","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2025.12.003_bib82","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/WNO.0000000000000113","article-title":"Parainfectious optic neuritis: children vs adults","volume":"34","author":"Rappoport","year":"2014","journal-title":"J Neuro Ophthalmol"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.003_bib83","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/ICU.0000000000000607","article-title":"Update on pediatric optic neuritis","volume":"30","author":"Lock","year":"2019","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ncl.2025.12.003_bib84","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejpn.2020.04.002","article-title":"High association of MOG-IgG in children with bilateral optic neuritis","volume":"27","author":"Wendel","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ncl.2025.12.003_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2024.01.003","article-title":"Clinical outcomes and anti-MOG antibodies in pediatric optic neuritis: prospective study","volume":"49","author":"Nair","year":"2024","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:21:32Z","timestamp":1776802892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861925000933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0733861925000933"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2025.12.003","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on the Acute and Maintenance Management of Optic Neuritis Including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody Disease","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}